

1 **Title: Importation, Antibiotics, and *Clostridium difficile* Infection in Veteran Long-**
2 **Term Care: A Multilevel Case-Control Study**

3
4 **Running Title: *C. difficile* Infection in Veteran Long-Term Care**

5
6 **Kevin A. Brown, PhD**

7 **Makoto Jones, MD**

8 **Nick Daneman, MD**

9 **Frederick R. Adler, PhD**

10 **Vanessa Stevens, PhD**

11 **Kevin E. Nechodom, BSc**

12 **Matthew B. Goetz, MD**

13 **Matthew H. Samore, MD**

14 **Jeanmarie Mayer, MD**

15
16 **Author Affiliations: Division of Epidemiology, University of Utah (Drs. Brown, Jones,**
17 **Stevens, Samore, Mayer and Mr. Nechodom), Salt Lake City Veterans Affairs**
18 **Healthcare System, (Drs. Brown, Jones, Samore, and Mayer), Dalla Lana School of**
19 **Public Health, University of Toronto (Dr. Brown), Public Health Ontario (Dr. Brown),**
20 **Sunnybrook Health Sciences Centre, University of Toronto (Dr. Daneman),**
21 **Department of Mathematics and Department of Biology, University of Utah (Dr.**
22 **Adler), Department of Pharmacotherapy, University of Utah (Dr. Stevens), Infectious**
23 **Diseases Section, Department of Medicine, Greater Los Angeles Veterans Affairs**
24 **Healthcare System and David Geffen School of Medicine at UCLA (Dr. Goetz)**

25
26 **Corresponding Author: Kevin Antoine Brown, PhD, Public Health Ontario, 480**
27 **University Ave, Toronto, Canada M5G1V2, kevin.brown@oahpp.ca**

28
29 **Abstract Word Count: 275 [excluding funding sources]**

30 **Main Text Word Count: 3499**

31 **Summary**

32

33 **Background:** While factors impacting an individual's susceptibility to *C. difficile* infection
34 are well understood, little is known about what drives differences in incidence across long-
35 term care settings.

36

37 **Objective:** To obtain a comprehensive picture of individual and regional factors that
38 impact *C. difficile* infection incidence.

39

40 **Design:** Multilevel longitudinal nested case-control study.

41

42 **Setting:** Veterans Health Administration (VHA) healthcare regions, from 2006 through
43 2012.

44

45 **Participants:** Long-term care residents.

46

47 **Measurements:** Individual-level risk factors included age, number of comorbid conditions,
48 and antibiotic exposure. Region-level risk factors included importation of acute care *C.*
49 *difficile* cases per 10,000 resident-days and antibiotic use per 1,000 resident-days. The
50 outcome was defined as an incident long-term care positive *C. difficile* test, without a
51 positive test in the prior 8 weeks.

52

53 **Results:** 6,012 cases (incidence=3.7 per 10,000 resident-days) were identified in 86
54 regions. Across regions, there was substantial variation in long-term care *C. difficile*
55 incidence (min=0.7, max=32.4), antibiotic use (min=60.9, max=370.2 per 1,000 resident-
56 days), and importation (min=2.8, max=341.3 per 10,000 resident-days). Together,
57 antibiotic use and importation explained 75% of the regional variation in *C. difficile*
58 incidence ($R^2=0.75$). Multilevel analyses showed that region-level factors impacted risk
59 above and beyond individual-level exposures (region antibiotic use, RR=1.45 per doubling,
60 95%CI: 1.24, 1.69; importation, RR=1.25 per doubling, 95%CI: 1.16, 1.34).

61

62 **Limitations:** Case identification was based on laboratory criteria. Admission of residents
63 with recent *C. difficile* infection from non-VHA acute care sources was not considered.

64

65 **Conclusions:** Only 25% of the variation in long-term care *C. difficile* infection incidence
66 remained unexplained after accounting for importation from acute care and antibiotic use,
67 suggesting that *C. difficile* infection control at acute care facilities and antimicrobial
68 stewardship may help reduce long-term care *C. difficile* incidence.

69

70 **Funding Sources:** U.S. Department of Veterans Affairs, Centers for Disease Control and
71 Prevention

72

73 **Introduction**

74
75 *Clostridium difficile* infection is a diarrheal disease that is associated with antibiotic and
76 healthcare exposures. *C. difficile* has the highest prevalence, morbidity, and mortality of any
77 healthcare-associated infection (1,2). Risk factors for acquisition of *C. difficile* have been
78 extensively studied and include age, comorbidity burden, abdominal surgery, feeding tube
79 use, and exposure to antibiotics and antacids (3). Almost all antibiotic classes are thought
80 to increase risk, but the magnitude of risk is especially high for antibiotics with activity
81 against gut flora and lacking activity against *C. difficile*, which include cephalosporins,
82 fluoroquinolones, and clindamycin (4,5). Antacids, especially proton pump inhibitors, are
83 thought to increase risk by reducing stomach acidity, thereby allowing increased numbers
84 of ingested *C. difficile* to reach the gut in a viable state.

85
86 Although clinical risk factors have been extensively studied, the environmental and facility-
87 level exposures that may drive *C. difficile* transmission have not. What is known is that *C.*
88 *difficile* is transmitted by the fecal-oral route and patients with symptomatic disease or
89 even asymptomatic colonization have high bacterial loads in their stool and shed infectious
90 spores into their environs for extended periods of time (6,7). Exposure of patients to
91 inpatient care unit-level disease pressure, measured as the daily number of infectious
92 patients with recent *C. difficile* infection present on the same inpatient care unit, predicts
93 increased risk of *C. difficile* infection (8). In addition to disease pressure, hospital care unit
94 antibiotic use has been shown to increase risk of acquisition, above and beyond individual-
95 level antibiotic exposure (9). This may be due to the higher likelihood of asymptomatic *C.*
96 *difficile* colonization and shedding among patients with recent antibiotic exposure (7)
97 which thereby creates a higher environmental *C. difficile* burden.

98
99 Long-term care facilities provide services to residents requiring assistance with activities
100 of daily living in a residential setting, skilled nursing, spinal cord injury care, and
101 rehabilitation. In long-term care, antimicrobial use is generally high, with the point
102 prevalence of antibiotic use around 8%, of which 25% to 75% may be inappropriate (10).
103 The impact of antimicrobial use on facility *C. difficile* infection incidence in long-term care
104 settings has never been explored. Further, long-term care residents have frequent contact
105 with acute care facilities and, as such, importation of hospital-onset *C. difficile* cases may be
106 an important risk factor for long-term care *C. difficile* infection incidence (11).

107
108 Models incorporating both individual- and facility-level risk factors can be used to
109 distinguish risk factors that impact individual susceptibility to disease from factors that
110 may be associated with the degree of environmental contamination and that may proxy
111 spore ingestion (12). The objective of this study was to obtain a comprehensive picture of
112 the individual- and region-level factors that drive *C. difficile* infection risk across Veterans
113 Health Administration (VHA) long-term care, with a specific interest in the role of
114 importation of acute care facility onset *C. difficile* infection and regional rates of antibiotic
115 use.

116
117 **Methods**

119 *Ethics Statement*

120

121 Study approval was obtained from the research ethics board of the Salt Lake City Veterans
122 Affairs Health Care System. The board waived the need for consent because there was no
123 contact with residents and their anonymity was assured.

124

125 *Study Design*

126

127 A retrospective study of VHA long-term care residents across 111 healthcare regions in the
128 7-year period from January 1, 2006 through December 31, 2012 was conducted. In VHA,
129 healthcare regions act as local healthcare systems and usually provide both acute and long-
130 term care services. In most of these regions, long-term care services were delivered in a
131 single facility (n=89), though in some regions care was distributed across 2 or more
132 locations (n=22). All long-term care facilities provide 24-hour nursing care and some
133 additionally provide psychiatric care, spinal cord injury care, or hospice care.

134

135 This retrospective study employed a multilevel longitudinal nested case-control design. To
136 accurately estimate resident risk, a multilevel model was used, which incorporated both
137 resident-level risk factors (characteristics of specific at-risk individuals), as well as region-
138 level risk factors (measures of the prevalence of residents that were likely to shed *C.*
139 *difficile* spores). To allow short-term pharmaceutical exposures to be measured in an
140 appropriate retrospective window, the analysis dataset was broken down into a
141 longitudinal, resident-day format. Since the resultant dataset was extensive, a nested case-
142 control design was used.

143

144 *Population*

145

146 Residents were considered at-risk of a long-term care onset *C. difficile* infection if they
147 resided in an inpatient VHA long-term care facility for ≥ 3 of the previous 28 days and did
148 not have a positive *C. difficile* test in the prior 8 weeks. Healthcare regions, and eligible
149 residents within them, were included in the risk set if there were at least 6 years of data
150 where both long-term and acute care censuses were above an average of 10 eligible, at-risk,
151 individuals per day for each month of the given year. Regions without acute care facilities
152 were excluded because imported *C. difficile* cases from non-VHA acute care facilities were
153 not captured and would have led to an underestimation of *C. difficile* importation in those
154 regions.

155

156 *Definition of Cases and Controls*

157

158 A resident was considered a case on the date of a positive *C. difficile* toxin test ≥ 3 days after
159 their long-term care admission and occurring at least 8 weeks from a previous positive test
160 (13). Positive *C. difficile* tests were identified from VHA microbiology data using natural
161 language processing (14). Eligible controls were resident-days that did not meet the case
162 definition, and could include resident days from individuals that later became cases. A 1%
163 unmatched simple random sample of eligible controls was selected for analysis.

164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207

Resident Risk Factors

The 7 resident risk factors assessed consisted of age, sex, days of acute care hospitalization within the previous 4 weeks, number of comorbid conditions, 3 pharmaceutical exposures, and days of follow-up time within the previous 4 weeks. The value of each time-varying variable was assessed for each day. For comorbidity count, acute and long-term care facility discharge diagnosis codes (ICD-9-CM) were used to assess the presence of 14 comorbidities in the preceding year, as per Charlson (15,16). For a given resident, the total number of comorbidities was summed. Three pharmaceutical exposure variables were assessed, each in a 4-week retrospective window: (i) proton pump inhibitors, (ii) any antibiotic, but excluding *C. difficile* treatment agents (metronidazole, oral vancomycin and fidaxomicin), and (iii) an antibiotic risk index with 4 mutually exclusive levels consisting of: high-risk (receipt of cephalosporins, fluoroquinolones, or clindamycin), medium-risk (receipt of penicillins, macrolides, or sulfonamides but no high-risk agents), or low-risk (receipt of tetracyclines), or no antibiotic receipt or receipt of *C. difficile* treatment agents only, based on a similar risk index developed in an independent cohort study (17).

Pharmaceutical exposure information was drawn from the VHA electronic medical record administration data, and included all courses given during inpatient care in VHA acute or long-term care facilities; community exposures were not considered. In addition to these 7 resident risk factors, a control variable for the duration of follow-up time, defined as the total number of days a given resident had a stay in a VHA acute or long-term care within the last 28 days was measured, and categorized into deciles.

Healthcare Region Risk Factors

The five regional risk factors measured were average resident age, average resident comorbidity count, proton pump inhibitor use, antibiotic use, and importation of acute care *C. difficile* cases. These five region-level risk factors were measured from the full resident population of the regions, because residents who were not at risk (i.e.: recently admitted residents with a recent positive *C. difficile* test) were just as likely or more likely to transmit *C. difficile*. Proton pump inhibitor use and antibiotic use (excluding the *C. difficile* treatment agents mentioned above) were each measured as days of therapy (DOT) per 1,000 resident-days. Exposure on a given day contributed one unit to the numerator, regardless of the number of specific agents, dosage, or number of doses administered on that day. Importation of acute care *C. difficile* cases was measured as the prevalence of residents in the region that had an acute care onset *C. difficile* infection in the previous 8 weeks, per 10,000 resident-days. Acute care onset *C. difficile* infection was defined as a resident with a positive *C. difficile* toxin test ≥ 3 days after their long-term care admission from an acute care facility.

Statistical Analyses

208 The incidence of *C. difficile* across the VHA, and within each region, was measured using the
209 weighted mean. In all statistical analyses, sampling weights of 1 for cases and 100 for
210 controls corresponded to the inverse of the probability of selection allowing analyses to
211 produce unbiased estimates of *C. difficile* incidence in the entire study population (18). The
212 minimum, 10th percentile (p10), 90th percentile (p90), and maximum *C. difficile* infection
213 incidence across regions were measured. Shrunken measures of *C. difficile* incidence, that
214 were robust to regression to the mean bias, were used for measuring robust dispersion
215 characteristics (19) (see appendix for methods).

216
217 The association between each of the 7 resident-level and 5 region-level predictors, and *C.*
218 *difficile* infection risk was assessed using 13 weighted Poisson generalized estimating
219 equation (GEE) regression models that controlled for duration of follow-up time, and with
220 clusters that corresponded to region. Duration of follow-up time was included as a control
221 covariate in each model. Within clusters, the independence covariance structure was used,
222 yielding sandwich variance estimators. For each of the 13 models, the marginal
223 standardization approach was used to obtain absolute estimates of incidence for each
224 exposure group (20). Confidence intervals for absolute estimates of incidence were
225 measured using 1000 cluster bootstrap resamples, where clusters corresponded to regions
226 (21). In order to provide an intuitive measurement of the global model fit for the regional
227 models, we also measured the proportion of region-level variance in incidence explained
228 (R^2) by dividing the sum squared residuals around the Poisson GEE model-based incidence
229 estimates (log-scale), by the sum squared residuals around the mean incidence. An
230 analogous multivariate region-level model was also built to obtain adjusted estimates,
231 which included all 5 region-level covariates.

232
233 In order to distinguish the direct and indirect effects of antibiotic use on resident *C. difficile*
234 risk, we fit two weighted Poisson GEE regression models for the association between
235 region-level antibiotic use and *C. difficile* incidence to residents with and without direct
236 antibiotic exposure in the previous 28-days.

237
238 A multilevel weighted Poisson GEE model was built that controlled for duration of follow-
239 up time and included individual-level factors of age, sex, days of acute care hospitalization
240 within the previous 28 days, comorbidity count, and pharmaceutical exposures in the
241 previous 28 days (antibiotic use and PPI use), comorbidity burden, importation of acute
242 care *C. difficile* cases and region antibiotic use. As such, the model included a total of 8
243 covariates, and accounted for region-level clustering.

244 245 *Sensitivity Analyses*

246
247 To better capture the region-level effects of low, medium, and high risk antibiotics and
248 capture them in a single variable, we measured a region-level antibiotic risk index that was
249 measured as DOT per 1,000 resident-days, but where days of therapy for high-risk
250 antibiotics were given a weight of 2, medium-risk antibiotics, a weight of 1, and low-risk
251 antibiotics, a weight of 0. This weighting scheme was adapted from a similar risk scale from
252 a meta-analysis of antibiotic exposures (4). This variable was included in a Poisson GEE
253 model that controlled for follow-up time and region-level clustering.

254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299

Data extraction and statistical software

Datasets were built using SQL Server Management Studio. Analyses were conducted using SAS and R software, using the *GLIMMIX* procedure for generalized linear mixed models and the *GENMOD* procedure for the GEE models.

Role of the Funding Source

This study was funded through the United States Centers for Disease Control and the Veterans Health Administration. The funders had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Results

Population and Nested Case-Control Sample Characteristics

86 regions met the inclusion criteria. In total, the population included 47,342 person-years of follow-up, of which 44,759 years met the criteria for being at risk for *C. difficile* infection. Per region, at-risk follow-up varied from 80 to 2,176 person-years (median=447 years). The 1% sampling of controls yielded a selection of 163,441 controls from across the 86 regions, and represented 55,504 unique residents. The number controls selected per region varied between 282 and 8,148, and the achieved sampling rate was stable across regions, varying from 0.9% to 1.1%.

Outcome

There were 6,012 cases of long-term care onset *C. difficile* infection, representing 5,499 unique residents. The sampling ratio was 27 controls for each case and the incidence rate of *C. difficile* infection was 3.7 cases per 10,000 at-risk resident-days. Across the 86 care regions, the median region-level incidence of *C. difficile* infection was 3.2 per 10,000 at-risk resident-days and there was a substantial variation in incidence across regions (min=0.6, p10=1.2, median=3.2, p90=8.3, max=31.0, range=48.31-fold, interdecile range [IDR]=6.96-fold). The dispersion of the shrunken incidence measurements remained elevated (min=0.7, p10=1.3, median=3.2, p90=7.9, max=29.9, range=40.11-fold, IDR=6.11-fold).

Resident Risk Factors

Residents with a history of acute care hospitalization in the previous 28 days had a 4.49-fold increase in the risk of developing *C. difficile* (95%CI: 4.25, 4.74, Table 1). Residents who received antibiotics in the previous 28 days were 7.07-fold more likely to develop a *C. difficile* infection (95%CI: 6.63, 7.54), and there was a positive gradient across levels of the antibiotic risk index.

300 *Healthcare Region Risk Factors*

301
302 In unadjusted analyses, the strongest predictors of region *C. difficile* incidence were region
303 antibiotic use (Figure 1, panel A, and Table 2, unadjusted incidence rate ratio [IRR]=2.86
304 per doubling of antibiotic use, 95%CI: 2.34, 3.49, $R^2=0.63$) and importation of acute care *C.*
305 *difficile* cases (Figure 1, panel B, unadjusted IRR=1.59 per doubling of importation, 95%CI:
306 1.43, 1.78, $R^2=0.50$). These two factors also showed dramatic variation across regions:
307 antibiotic use varied over 6-fold (min=70.0, p10=92.1, median=137.0, p90=248.3,
308 max=370.2, range=6.07-fold, IDR=2.70-fold) and importation of acute care *C. difficile* cases
309 varied over 100-fold (min=2.9, p10=17.3, median=47.7, p90=123.2, max=341.3,
310 range=118.79-fold, IDR=7.11-fold).

311
312 The remaining 3 region-level risk factors yielded weaker associations with region-level *C.*
313 *difficile* incidence. In the adjusted analysis that included all 5 region-level covariates,
314 antibiotic use and importation of acute care *C. difficile* cases remained significantly
315 associated with increased region-level *C. difficile* incidence, but the remaining three region-
316 level covariates were not significant. Dropping the three non-significant region-level
317 covariates yielded a parsimonious model that was statistically equivalent (score $\chi^2_{3df}=1.3$
318 $p=0.72$) to the 5-covariate model. This parsimonious model included just antibiotic use and
319 importation of acute care cases ($R^2=0.75$, Figure 1, panel C).

320
321 When measured in residents with and without direct antibiotic exposure separately, a
322 strong dose-response relationship between region antibiotic use and *C. difficile* incidence
323 was observed in both groups (Figure 2). This association was stronger in residents without
324 direct exposure (IRR=2.81 per doubling, 95%CI: 2.20, 3.58, $R^2=0.49$), than among residents
325 with direct exposure (IRR=1.90 per doubling, 95%CI: 1.55, 2.33, $R^2=0.39$). Antibiotic users
326 were at greater relative risk, but lower absolute risk, in low antibiotic use regions as
327 compared to high antibiotic use regions (Figure 2).

328 329 *Multilevel Model*

330
331 The multilevel model of risk (Table 3), which included 5 individual-level covariates, in
332 addition to region antibiotic use and region importation of acute care *C. difficile* cases,
333 demonstrated that antibiotic-use had both a direct, resident-level impact on risk (IRR=4.81,
334 95%CI: 4.37, 5.28), in addition to an indirect impact on risk via region antibiotic use
335 (IRR=1.36 per doubling, 95%CI: 1.15, 1.60). Importation of acute care *C. difficile* cases also
336 continued to impact risk in this model (IRR=1.23, 95%CI: 1.14, 1.33).

337 338 *Sensitivity Analyses*

339
340 In order to distinguish the role of low- and high-risk antibiotics in driving region-level *C.*
341 *difficile* infection risk, we conducted a sensitivity analysis that used a region-level antibiotic
342 risk index having larger weights for high-risk antibiotics. In this model, the antibiotic risk
343 index yielded a fit that was very similar to antibiotic use (unadjusted IRR=2.71 per
344 doubling, 95%CI=2.26, 3.25, $R^2=0.58$). The antibiotic risk index was strongly correlated

345 with total antibiotic use ($R^2=0.96$). Additional sensitivity analyses are presented in the
346 appendix.

347 348 **Conclusions**

349
350 In this comprehensive nested case-control study of *C. difficile* infection risk across long-
351 term care facilities in 86 VHA healthcare regions, (i) region rates of *C. difficile* infection
352 varied 40-fold, (ii) region antibiotic use varied over 6-fold and importation of acute care *C.*
353 *difficile* cases varied over 100-fold, (iii) region antibiotic use and importation of acute care
354 *C. difficile* cases explained 75% of the variability in region long-term care onset of *C. difficile*
355 infection incidence, and (iv) region antibiotic prescribing impacted resident risk above and
356 beyond individual receipt of antibiotics.

357
358 The median daily point prevalence of antibiotic use in long-term care was 14%, which is
359 double that of previous reported estimates of antibiotic use (10,22). Antibiotic use was the
360 primary driver of differences in *C. difficile* rates across VHA long-term care facilities, and
361 total antibiotic use drove risk more than the specific mix of high- and low-risk antibiotics
362 dispensed. Antimicrobial stewardship initiatives geared toward *C. difficile* reduction in
363 long-term care could consider reductions of total antibiotic usage as a primary target.

364
365 Furthermore, important herd effects of antibiotic use were identified. Residents with direct
366 antibiotic receipt, as well as those without direct receipt, were both more likely to develop
367 *C. difficile* infection in regions with higher levels of antibiotic use. Such herd-effects of
368 antibiotic prescribing on *C. difficile* infection were hypothesized nearly two decades ago
369 (23) and since then, only two studies have empirically analyzed the indirect effects of
370 antibiotic use on *C. difficile* incidence with contradictory findings (9,24). This study
371 identified that the direct effects of antibiotic use were heterogeneous: antibiotic users were
372 at greater relative risk, but lower absolute risk, in low antibiotic use regions as compared
373 to high antibiotic use regions. This may help to explain the substantially larger relative
374 risks of antibiotics observed in community (4) as compared to acute care settings (5).

375
376 This study provides evidence that antibiotic use drives *C. difficile* transmission within long-
377 term care facilities. The mechanism of transmission may be that in facilities with high
378 antibiotic use, there is increased prevalence of residents with asymptomatic *C. difficile*
379 colonization, who, when exposed to antibiotics, become more effective *C. difficile* shedders
380 (7). This research supports efforts in many countries to institute regional and care-system-
381 wide antibiotic stewardship initiatives that aim to reduce unnecessary prescribing (25),
382 and also suggests that the scope of antibiotic reporting also consider long-term care
383 antibiotic use as intrinsic to regional stewardship programs.

384
385 Previous studies have measured prevalence of colonization with *C. difficile* on admission to
386 acute care hospitals (26,27) and noted that an important proportion of *C. difficile* infections
387 in long-term care appeared to have acquired the bacteria in acute care facilities (11,28,29).
388 Importation has been shown to be an important predictor of facility-level methicillin-
389 resistant *Staphylococcus aureus* colonization (30). However, the impact of importation on
390 rates of long-term care onset *C. difficile* has never been assessed. In this study, the

391 prevalence of residents with acute care onset *C. difficile* infection in the previous 8-weeks
392 was, on average, 45.5 per 10,000 resident-days and varied over a 100-fold range. The
393 importation of residents with acute care onset *C. difficile* acted in concert with antibiotic
394 use in predicting long-term care onset *C. difficile* infection rates. Our results suggest that
395 infection prevention and control teams may need to take special measures in long-term
396 care facilities that receive residents from hospitals with elevated rates of *C. difficile*
397 infection.

398
399 Our study has a number of limitations. First, our outcome considered only laboratory-
400 identified *C. difficile*, which do not necessarily correspond with clinical infections. This is
401 especially a concern given heterogeneity in testing practices across regions. However, one
402 study has shown that over 90% of laboratory-identified *C. difficile* cases in the VHA were
403 clinically confirmed (31). Second, our study only included importation from VHA acute care
404 facilities and did not consider *C. difficile* cases from all sources. As such, this study may have
405 underestimated the role of importation. Furthermore, this study only considered
406 importation in a 56-day window from a positive *C. difficile* test. Third, we had no molecular
407 information on the strains of *C. difficile* that infected residents and therefore the risk levels
408 incurred by antibiotics represented averages across the strains in each region. Our results
409 may not be representative or generalizable to other countries where strain distributions
410 differ. Finally, this study did not incorporate outpatient pharmaceutical exposures and
411 considered only a brief antibiotic exposure assessment window, both factors that
412 sensitivity analyses suggested could have led to an underestimation of antibiotic effects.

413
414 This study of long-term care *C. difficile* infection is the largest and most comprehensive to
415 date, and provides a detailed portrait of risk, including both individual and regional factors.
416 We found that variation in region antimicrobial use was strongly associated with variation
417 in the *C. difficile* infection incidence in long-term care. In regions with high rates of *C.*
418 *difficile* in long-term care, coordinated antimicrobial stewardship initiatives that reduce
419 inappropriate prescribing have the potential to substantially reduce rates of *C. difficile*
420 infection.

421

422 **Acknowledgements**

423

424 **Author Contributions:** Drs. Brown, Mayer, and Jones had full access to all of the data in the
425 study and take responsibility for the integrity of the data and the accuracy of the data
426 analysis.

427

428 Study conception and design: Brown, Adler, Mayer, Jones, Samore. Acquisition of the data:
429 Brown, Mayer, Jones, Samore, Nechodom. Analysis or interpretation of the data: All
430 authors. Drafting of the manuscript: Brown. Critical revision of the manuscript: All authors.
431 Administrative, technical, or material support: Jones, Samore, Nechodom. Study
432 supervision: Brown, Mayer, Jones, Samore.

433

434 **Disclosures:** All authors declare no conflicts of interest.

435

436 **Disclaimer:** The views expressed in this article are those of the authors and do not
437 necessarily reflect the position or policy of the U.S. Department of Veterans Affairs, Centers
438 for Disease Control and Prevention, or U.S. government.

439

440 **Reproducible Research Statement:** Statistical code: available from Dr. Brown (e-mail,
441 kevin.brown@oahpp.ca). Study protocol and data set: not available.

442

443 **References**

- 444
- 445 1. Magill SS, Edwards JR, Bamberg W, Beldavs ZG, Dumyati G, Kainer MA, et al. Multistate
446 Point-Prevalence Survey of Health Care–Associated Infections. *N Engl J Med*. 2014 Mar
447 27;370(13):1198–208.
- 448 2. Kwong JC, Ratnasingham S, Campitelli MA, Daneman N, Deeks SL, Manuel DG, et al. The
449 Impact of Infection on Population Health: Results of the Ontario Burden of Infectious
450 Diseases Study. Braitstein P, editor. *PLoS ONE*. 2012 Sep 4;7(9):e44103.
- 451 3. Bignardi GE. Risk factors for *Clostridium difficile* infection. *J Hosp Infect*. 1998;40(1):1–
452 15.
- 453 4. Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-Analysis of Antibiotics and the
454 Risk of Community-Associated *Clostridium difficile* Infection. *Antimicrob Agents*
455 *Chemother*. 2013 May;57(5):2326–32.
- 456 5. Slimings C, Riley TV. Antibiotics and hospital-acquired *Clostridium difficile* infection:
457 update of systematic review and meta-analysis. *J Antimicrob Chemother*. 2014
458 Apr;69(4):881–91.
- 459 6. Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. Persistence of Skin
460 Contamination and Environmental Shedding of *Clostridium difficile* during and after
461 Treatment of *C. difficile* Infection. *Infect Control Hosp Epidemiol*. 2010 Jan;31(1):21–7.
- 462 7. Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ. Asymptomatic
463 carriers are a potential source for transmission of epidemic and nonepidemic
464 *Clostridium difficile* strains among long-term care facility residents. *Clin Infect Dis Off*
465 *Publ Infect Dis Soc Am*. 2007 Oct 15;45(8):992–8.
- 466 8. Dubberke ER, Reske KA, Olsen MA, McMullen KM, Mayfield JL, McDonald LC, et al.
467 Evaluation of *Clostridium difficile*-associated disease pressure as a risk factor for *C*
468 *difficile*-associated disease. *Arch Intern Med*. 2007 May 28;167(10):1092–7.
- 469 9. Brown K, Valenta K, Fisman D, Simor A, Daneman N. Hospital Ward Antibiotic
470 Prescribing and the Risks of *Clostridium difficile* Infection. *JAMA Intern Med*. 2015 Apr
471 1;175(4):626–33.
- 472 10. Nicolle LE, Bentley DW, Garibaldi R, Neuhaus EG, Smith PW. Antimicrobial use in long-
473 term-care facilities. SHEA Long-Term-Care Committee. *Infect Control Hosp Epidemiol*.
474 2000 Aug;21(8):537–45.
- 475 11. Laffan AM, Bellantoni MF, Greenough WB, Zenilman JM. Burden of *Clostridium difficile*-
476 associated diarrhea in a long-term care facility. *J Am Geriatr Soc*. 2006 Jul;54(7):1068–
477 73.

- 478 12. Diez Roux AV, Aiello AE. Multilevel Analysis of Infectious Diseases. *J Infect Dis.* 2005
479 Feb;191(s1):S25–33.
- 480 13. Multidrug-Resistant Organism & Clostridium difficile Infection (MDRO/CDI) Module. In:
481 CDC The National Healthcare Safety Network (NHSN) Patient Safety Component (PSC)
482 Manual [Internet]. U.S. Centers for Disease Control and Prevention (CDC); [cited 2015
483 Jan 23]. Available from:
484 http://www.cdc.gov/nhsn/PDFs/pscManual/12pscMDRO_CDADcurrent.pdf
- 485 14. Jones M, DuVall SL, Spuhl J, Samore MH, Nielson C, Rubin M. Identification of
486 methicillin-resistant Staphylococcus aureus within the Nation’s Veterans Affairs
487 Medical Centers using natural language processing. *BMC Med Inform Decis Mak.*
488 2012;12(1):34.
- 489 15. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity
490 index. *J Clin Epidemiol.* 1994;47(11):1245–51.
- 491 16. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms
492 for defining comorbidities in ICD-9-CM and ICD-10 administrative data. *Med Care.*
493 2005;43(11):1130.
- 494 17. Brown KA, Fisman DN, Moineddin R, Daneman N. The magnitude and duration of
495 Clostridium difficile infection risk associated with antibiotic therapy: a hospital cohort
496 study. *PloS One.* 2014;9(8):e105454.
- 497 18. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. *J Clin*
498 *Epidemiol.* 1999 Dec;52(12):1165–72.
- 499 19. Christiansen CL. Improving the Statistical Approach to Health Care Provider Profiling.
500 *Ann Intern Med.* 1997 Oct 15;127(8_Part_2):764.
- 501 20. Austin PC. Absolute risk reductions, relative risks, relative risk reductions, and
502 numbers needed to treat can be obtained from a logistic regression model. *J Clin*
503 *Epidemiol.* 2010 Jan;63(1):2–6.
- 504 21. Ren S, Lai H, Tong W, Aminzadeh M, Hou X, Lai S. Nonparametric bootstrapping for
505 hierarchical data. *J Appl Stat.* 2010 Sep;37(9):1487–98.
- 506 22. Daneman N, Gruneir A, Newman A, Fischer HD, Bronskill SE, Rochon PA, et al. Antibiotic
507 use in long-term care facilities. *J Antimicrob Chemother.* 2011 Dec 1;66(12):2856–63.
- 508 23. Starr JM, Rogers TR, Impallomeni M. Hospital-acquired Clostridium difficile diarrhoea
509 and herd immunity. *The Lancet.* 1997 Feb 8;349(9049):426–8.
- 510 24. Pakyz AL, Jawahar R, Wang Q, Harpe SE. Medication risk factors associated with
511 healthcare-associated Clostridium difficile infection: a multilevel model case-control

- 512 study among 64 US academic medical centres. J Antimicrob Chemother. 2014 Apr
513 1;69(4):1127–31.
- 514 25. Trivedi KK, Dumartin C, Gilchrist M, Wade P, Howard P. Identifying Best Practices
515 Across Three Countries: Hospital Antimicrobial Stewardship in the United Kingdom,
516 France, and the United States. Clin Infect Dis. 2014 Oct 15;59(suppl 3):S170–8.
- 517 26. Samore MH, DeGirolami PC, Tlucko A, Lichtenberg DA, Melvin ZA, Karchmer AW.
518 Clostridium difficile colonization and diarrhea at a tertiary care hospital. Clin Infect
519 Dis Off Publ Infect Dis Soc Am. 1994 Feb;18(2):181–7.
- 520 27. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium
521 difficile by Hospitalized Patients: Evidence for Colonized New Admissions as a Source
522 of Infection. J Infect Dis. 1992;166(3):561–7.
- 523 28. Mylotte JM. Surveillance for *Clostridium difficile* —Associated Diarrhea in Long-Term
524 Care Facilities: What You Get Is Not What You See. Infect Control Hosp Epidemiol.
525 2008 Aug;29(8):760–3.
- 526 29. Guerrero DM, Nerandzic MM, Jury LA, Chang S, Jump RL, Donskey CJ. Clostridium
527 difficile infection in a Department of Veterans Affairs long-term care facility. Infect
528 Control Hosp Epidemiol. 2011 May;32(5):513–5.
- 529 30. Jones M, Ying J, Huttner B, Evans M, Maw M, Nielson C, et al. Relationships between the
530 importation, transmission, and nosocomial infections of methicillin-resistant
531 Staphylococcus aureus: an observational study of 112 Veterans Affairs Medical
532 Centers. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014 Jan;58(1):32–9.
- 533 31. Evans ME, Simbartl LA, Kralovic SM, Jain R, Roselle GA. Clostridium difficile infections in
534 Veterans Health Administration acute care facilities. Infect Control Hosp Epidemiol.
535 2014 Aug;35(8):1037–42.
- 536

537 **Figure legends**

538

539 Figure 1. The association between the incidence of long-term care onset *C. difficile* infection
540 and importation of acute care *C. difficile* cases (panel A), antibiotic use (panel B), and both
541 of these variables (panel C), across 86 VHA healthcare regions, 2006 to 2012. Point-size
542 represents the duration of follow-up in resident-days within each region: (small point) less
543 than 100,000, (medium point) 100,000 to 199,999, (large point) 200,000 or more. For
544 panel C, regression lines represent the estimated association between antibiotic use and *C.*
545 *difficile* infection incidence at the 5th (lowest line), 50th (middle line), and 95th (highest line)
546 percentiles of importation.

547

548 Figure 2. The association between antibiotic use and the incidence of long-term care onset
549 *C. difficile* infection among residents with and without direct antibiotic use across 86 VHA
550 regions, 2006 to 2012. Point-size represents the duration of follow-up, in resident-days,
551 within each unit: (small point) less than 100,000, (medium point) 100,000 to 199,999,
552 (large point) 200,000 or more.

553

554 **Appendix**

555

556 *Robust Measures of Dispersion*

557

558 Because measurement error can inflate estimates of the range and interdecile range, we
559 also calculated the minimum, p10, p90, and maximum on the predicted region-level
560 incidence rates from a generalized linear mixed model that included only the intercept
561 fixed effect and random intercepts for regions. These estimates provided estimates of range
562 and interdecile range that were shrunken toward the ensemble mean in proportion to the
563 degree of potential measurement error, and thus robust against regression to the mean
564 bias (19).

565

566 *Methods for Additional Sensitivity Analyses*

567

568 We conducted different sensitivity analyses in order to explore the robustness of the
569 region-level estimates from the main adjusted multilevel model, presented in Table 3. Each
570 sensitivity analysis consisted of a slight modification to the variable specification or the
571 source population of the main multilevel model presented in Table 3.

572

- 573 • The first sensitivity analysis considered the impacts of region antibiotic use and
574 importation of *C. difficile* cases on *C. difficile* risk in a more causally relevant 8-week
575 retrospective window. To do this we built a region-day dataset that included, for each
576 region, one observation for each day of the study period. For each region-day,
577 importation of *C. difficile* cases and antibiotic use within the region on that given day
578 were measured. We then calculated the mean region-level importation and antibiotic
579 use across a 56-day retrospective window and this was merged into the nested case
580 control dataset, matching on region and day. These two time-varying region variables
581 were then used in the multilevel analyses, rather than the time-fixed versions that were
582 used in the main analysis.
- 583 • The second sensitivity analysis explored the impact of including only residents who
584 were present in a VHA acute or long-term care facility in each of the prior 28 days
585 because they had the most accurate exposure assessment for pharmaceutical
586 exposures.
- 587 • The third sensitivity analysis included an additional covariate that identified patients
588 whose most recent antibiotic exposure was in a 5-12 week retrospective window.
- 589 • In order to investigate whether the sample size for the nested case control study was
590 sufficiently large, the fourth sensitivity analysis included the same variables as the main
591 analysis presented in Table 3, except that a 5% control sample was used rather than a
592 1% control sample.
- 593 • In order to identify whether importation from, other, non-VHA acute care sources may
594 impact the analysis results, the fifth sensitivity analysis included the same variables as
595 the main analysis presented in Table 3, except this analysis was limited to only those
596 regions in which at least 10% of the resident population had VHA acute care contact in
597 the prior 28 days. This subset of regions was likely to have more accurate identification

598 of importation because in these regions the resident population was so closely tied to
599 VHA acute care facilities.

600

601 *Results for Additional Sensitivity Analyses*

602

- 603 • Sensitivity analysis 1: When the two region risk factors were considered as time-
604 varying covariates within the multilevel model described above, the dose-response
605 association between each variable and increased *C. difficile* incidence remained present
606 (Appendix Table, IRR for mean region-level antibiotic use in last 56 days, per
607 doubling=1.61, 95%CI: 1.39, 1.87, IRR for mean importation of acute care *C. difficile*
608 cases in last 56 days, per doubling=1.14, 95%CI: 1.10, 1.18).
- 609 • Sensitivity analysis 2: When the analysis sample for the main multilevel model was
610 restricted to residents with complete 28-day follow-up, the estimated association for
611 between direct antibiotic use and region-level antibiotic use actually increased
612 substantially.
- 613 • Sensitivity analysis 3: When a variable capturing the impact antibiotic exposure in the
614 previous 5-12 weeks was added to the main multilevel model, the estimated association
615 for direct antibiotic use in the previous 4-week period increased, while region-level
616 antibiotic use remained unchanged.
- 617 • Sensitivity analysis 4: The estimates from this sensitivity analysis were almost exactly
618 identical to our main analysis, suggesting that our 1% control sample size was
619 sufficient.
- 620 • Sensitivity analysis 5: Across regions, the proportion of residents that had acute care
621 contact in the prior 28 days varied from 5.2% to 62.4%. There were 77 regions in
622 which, on average, at least 10% of residents had recent contact in the prior 28 days
623 with VHA acute care. The analysis results were almost identical to the main analysis
624 (not shown). In this model, the impact of importation of acute care cases was identical
625 (IRR per doubling, 1.23, 95% CI: 1.13, 1.34).

Tables

Table 1. Individual-Level Risk Factors for *C. difficile* Infection

	Cases (N, %)	Controls (N, %)	Incidence Rate Ratio* (95%CI)	Incidence Rate* (per 10,000 resident-days)
Gender				
Female	130 (2.2)	5287 (3.2)	Reference	2.3 (1.8, 3.0)
Male	5882 (97.8)	158154 (96.8)	1.52 (1.23, 1.87)	3.5 (3.0, 4.0)
Age				
Less than 60	902 (15.0)	27716 (17.0)	Reference	3.0 (2.6, 3.5)
60 to 69	1664 (27.7)	42366 (25.9)	1.23 (1.14, 1.34)	3.7 (3.1, 4.3)
70 to 79	1398 (23.3)	36105 (22.1)	1.23 (1.13, 1.34)	3.7 (3.1, 4.2)
80 and over	2048 (34.1)	57254 (35.0)	1.17 (1.08, 1.27)	3.5 (3.0, 4.0)
Hospitalization history in prior 28 days				
None	2921 (48.6)	133844 (81.9)	Reference	2.2 (1.9, 2.5)
Any	3091 (51.4)	29597 (18.1)	4.49 (4.25, 4.74)	9.9 (8.8, 11.0)
1 to 7 days in hospital	1343 (22.3)	16037 (9.8)	3.65 (3.41, 3.91)	8.0 (7.0, 9.2)
8 to 14 days in hospital	1102 (18.3)	9454 (5.8)	4.95 (4.59, 5.34)	10.9 (9.5, 12.3)
15 to 28 days in hospital	646 (10.7)	4106 (2.5)	6.92 (6.33, 7.56)	15.2 (13.3, 17.4)
Charlson Comorbidities				
None	1246 (20.7)	67874 (41.5)	Reference	1.8 (1.5, 2.1)
1 to 2	2613 (43.5)	58708 (35.9)	2.28 (2.13, 2.44)	4.1 (3.6, 4.7)
3 or more	2153 (35.8)	36859 (22.6)	3.04 (2.83, 3.26)	5.5 (4.8, 6.2)
Pharmaceutical exposures in previous 28 days				
Proton pump inhibitor				
None	2214 (36.8)	83443 (51.1)	Reference	2.5 (2.2, 2.9)
Any	3798 (63.2)	79998 (48.9)	1.76 (1.67, 1.86)	4.5 (3.9, 5.1)
Antibiotic Risk Class				
None	1165 (19.4)	105234 (64.4)	Reference	1.1 (1.0, 1.3)
Any	4847 (80.6)	58207 (35.6)	7.07 (6.63, 7.54)	7.8 (6.9, 8.8)
Low or no risk agents†	27 (0.4)	1949 (1.2)	1.26 (0.86, 1.85)	1.4 (0.9, 2.0)
Medium risk agents‡	974 (16.2)	19368 (11.9)	4.40 (4.04, 4.79)	4.9 (4.3, 5.5)
High risk agents §	3846 (64.0)	36890 (22.6)	8.79 (8.23, 9.39)	9.7 (8.6, 11.0)

*Adjusted for days of follow-up in prior 28 days, † Residents with only tetracycline exposure in previous 28 days, ‡ Residents with penicillin, macrolide, or sulfanamide exposures, but no high-risk agent exposures, § Residents with carbapenem, monobactam, cephalosporin, fluoroquinolone, or clindamycin exposures, irrespective of other antibiotic exposures

Table 2. Predictors of Region-Level Long-Term Care *C. difficile* Infection Incidence

	Unadjusted IRR (95%CI)	Adjusted* IRR (95%CI)
Average patient age, per 1 y increase	0.90 (0.85, 0.95)	0.97 (0.93, 1.02)
Average comorbidity count, per increase of 0.1	1.14 (1.10, 1.19)	0.99 (0.95, 1.03)
Proton pump inhibitor use per 1,000 resident-days, per increase of 100	1.26 (1.05, 1.51)	1.02 (0.91, 1.14)
Antibiotic use per 1,000 residents-days, per doubling	2.86 (2.34, 3.49)	2.08 (1.63, 2.64)
Importation of acute care <i>C. difficile</i> cases, per 10,000 patient-days, per doubling	1.59 (1.43, 1.78)	1.29 (1.18, 1.41)

IRR, incidence rate ration

* the adjusted model included all 5 region-level covariates

Table 3. Summary of Individual- and Region-Level Risk Factors for *C. difficile* Infection.

	Incidence Rate Ratio* (95%CI)
Individual-level	
Male	1.41 (1.14, 1.76)
Age	
Less than 60	Reference
60 to 69	1.23 (1.12, 1.34)
70 to 79	1.31 (1.19, 1.45)
80 and over	1.49 (1.34, 1.65)
Acute care hospitalization in previous 28 days	1.85 (1.71, 2.01)
Charlson Comorbidities	
None	Reference
1 to 2	1.28 (1.17, 1.39)
3 or more	1.50 (1.37, 1.63)
Pharmaceutical exposures in previous 28 days	
Antibiotic	4.81 (4.37, 5.28)
Proton pump inhibitor	1.29 (1.21, 1.38)
Region-level	
Antibiotic use, per doubling	1.36 (1.15, 1.60)
Importation of acute care <i>C. difficile</i> cases, per doubling	1.23 (1.14, 1.33)

* This model included adjustment for days of follow-up in prior 28 days


Appendix Table. Summary of Sensitivity Analyses for Adjusted Predictors of *C. difficile* Incidence. All numbers represent incidence rate ratios and 95% confidence intervals from multilevel Poisson GEE models that included adjustment for days of follow-up.

Sensitivity Analysis	Sensitivity Analysis 1: Time-varying region-level exposures	Sensitivity Analysis 2: Subset of residents with 28-days of follow-up	Sensitivity Analysis 3: 12-week antibiotic exposure window	Sensitivity Analysis 4: Larger 5% control sample size
Resident-level				
Male	1.41 (1.13, 1.75)	1.44 (1.11, 1.87)	1.42 (1.14, 1.77)	1.42 (1.14, 1.76)
Age				
Less than 60	Reference	Reference	Reference	Reference
60 to 69	1.26 (1.16, 1.38)	1.17 (1.06, 1.29)	1.23 (1.13, 1.35)	1.24 (1.14, 1.34)
70 to 79	1.31 (1.19, 1.45)	1.23 (1.10, 1.38)	1.32 (1.19, 1.45)	1.33 (1.21, 1.47)
80 and over	1.49 (1.34, 1.64)	1.35 (1.22, 1.50)	1.49 (1.35, 1.65)	1.50 (1.36, 1.66)
Acute care hospitalization in previous 28 days	1.91 (1.76, 2.07)	2.09 (1.92, 2.26)	1.86 (1.71, 2.02)	1.87 (1.71, 2.03)
Charlson Comorbidities				
None	Reference	Reference	Reference	Reference
1 to 2	1.29 (1.19, 1.40)	1.53 (1.36, 1.72)	1.22 (1.13, 1.33)	1.27 (1.17, 1.37)
3 or more	1.50 (1.38, 1.64)	1.73 (1.54, 1.94)	1.42 (1.30, 1.55)	1.48 (1.35, 1.61)
Antibiotic use				
None*	Reference	Reference	Reference	Reference
Antibiotic use in previous 4 weeks	4.71 (4.28, 5.17)	5.04 (4.50, 5.64)	6.91 (6.08, 7.85)	4.78 (4.35, 5.25)
Antibiotic use in previous 5-12 weeks	NA	NA	2.34 (2.08, 2.63)	NA
Proton pump inhibitor use in previous 4 weeks	1.28 (1.20, 1.37)	1.22 (1.13, 1.32)	1.28 (1.19, 1.36)	1.28 (1.20, 1.37)
Region-level				
Antibiotic use, per doubling	NA	1.45 (1.23, 1.72)	1.35 (1.14, 1.59)	1.36 (1.16, 1.61)
Importation of acute care <i>C. difficile</i> cases, per doubling	NA	1.22 (1.13, 1.32)	1.23 (1.14, 1.33)	1.23 (1.14, 1.33)
Region-level exposures in the previous 56-day period				
Antibiotic use, per doubling	1.61 (1.39, 1.87)	NA	NA	NA
Importation of acute care <i>C. difficile</i> cases, per doubling	1.14 (1.10, 1.18)	NA	NA	NA

GEE, generalized estimating equation


* For sensitivity analysis 3, the referent group included residents with no antibiotic exposure in the previous 84 days. For all other sensitivity analyses, the referent category included residents with no antibiotic exposure in the previous 28 days only.

C. difficile infection incidence, per 10,000 resident-days




Importation of acute care *C. difficile* cases, per 10,000 resident-days

C. difficile infection incidence, per 10,000 resident-days



Antibiotic use, per 1,000 resident-days

C. difficile infection incidence, per 10,000 resident-days



Antibiotic use, per 1,000 resident-days

C. difficile infection incidence, per 10,000 resident-days

